高危型人乳头瘤病毒(HPV)持续感染与多种肿瘤密切相关，治疗性疫苗是治疗HPV相关疾病的有效手段。利用免疫佐剂是提高疫苗免疫原性的有效方法。课题组先前利用poly(I:C)显著提高了HPV16E7多肽疫苗的免疫原性。然而，poly(I:C)在体内稳定性差、靶向性不强。在体外用佐剂活化效应细胞是解决这些问题的明智选择之一。树突状细胞(DCs)是体内固有免疫和适应性免疫之间的纽带，强大的抗原呈递功能能诱导抗原特异性T细胞反应。DC来源的外泌体(exosomes)因含多种免疫分子，近年被广泛用来做免疫治疗。但目前疗效有限，可能由于缺乏其他必要的活化信号。本研究旨在利用Toll样受体激动剂联合HPV抗原肽在体外刺激活化DC细胞，通过收集DC细胞分泌的exosomes（Dex），体内外验证Dexo的免疫原性，考证Dexo的体内抗HPV感染效应，探索基于exosomes的HPV疫苗策略的可行性。

High-risk human papillomavirus (HPV) persisted infections are associated with a variety of malignant neoplasms. Therapeutic vaccination is an effective method for treating HPV related diseases. Using immune adjuvant can improve the immunogenicity of the vaccine effectively. we have approved the immunogenicity of HPV16E7 peptide vaccine increased by poly (I:C). However, the application of the adjuvant is restricted by its poor stability in the body, poor targeting performance. It is wise to stimulate the target cells using adjuvant in vitro.Dendritic cells are the ligament between the innate and adaptive immune system as powerful antigen-presenting cells capable of inducing antigen-specific T cell responses. DCs derived exosome(Dexo) being widely used for immune therapy because its contains several immunologically relevant components,But the efficacy is poor. we speculate it is lack of other necessary activation signals. This study aimed at using toll like receptor agonist combined with HPV antigen peptide to activate DCs in vitro, validation Dexo immunogenicity and anti-HPV infection effect in vitro and in vivo. To explore the feasibility of exosomes-based HPV vaccine strategies.